Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AfBPP of α-helix mimetics in SJSA-1 cells

ABSTRACT: A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the affinity-based protein profiling of three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Amrita Date

LAB HEAD: Anna Barnard

PROVIDER: PXD063384 | Pride | 2026-08-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	AD_MS_052_DMSO_A_S3-B5_1_7930.d.zip	Other
	AD_MS_052_DMSO_B_S3-B10_1_7936.d.zip	Other
	AD_MS_052_DMSO_C_S3-H3_1_7943.d.zip	Other
	AD_MS_052_DMSO_D_S3-H8_1_7950.d.zip	Other
	AD_MS_052_NP_A_S3-B9_1_7935.d.zip	Other

Items per page:

1 - 5 of 24

Similar Datasets

AfBPP of pyrrolopyrimidine α-helix mimetics

Project description:A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the affinity-based protein profiling of three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

2026-08-05 | PXD063432 | Pride

AfBPP of oxopiperazine α-helix mimetics

2026-08-05 | PXD063387 | Pride

AfBPP of N-substituted oligobenzamide α-helix mimetics

2026-08-05 | PXD063390 | Pride

AfBPP of Navtemadlin probes in SJSA-1 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes of Navtemadlin. This data shows the proteins enriched upon treatment of SJSA-1 cells with these probes.

2025-04-28 | PXD058033 | Pride

Whole proteome characterisation following treatment with α-helix mimetic inhibitors of MDM2

Project description:A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the changes to the whole protoeme of SJSA-1 osteosarcoma cells following treatment with three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

2026-08-05 | PXD063398 | Pride

AfBPP of Navtemadlin probes in MCF-7 cells

2025-04-28 | PXD058036 | Pride

Whole proteome time course experiment in SJSA-1 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we test the effect of Navtemadlin treatment on protein expression in SJSA-1 cells over the course of 24 h.

2025-04-28 | PXD058053 | Pride

Whole proteome experiment to validate treatment conditions in SJSA-1 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes of Navtemadlin. This data shows the validation of treatment conditions through whole proteome proteomics experiments in order to ensure that the expression of key proteins such as MDM2 is uniform across conditions.

2025-04-28 | PXD058047 | Pride

Comparison of SJSA-1 and MCF-7 whole proteome after Navtemadlin treatment

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we compare the whole proteme of MCF-7 and SJSA-1 cells following Navtemadlin treatment in order to gain an insight into the cause of the observed differences in the off-target profile of this molecule in the two cell lines.

2025-04-28 | PXD058081 | Pride

Optimised Sample Handling Minimises Peptide Adsorption to Plastics to Enable High Sensitivity Evosep Based Chemical Proteomics

Project description:Chemical proteomics approaches often yield low peptide recovery because they aim to enrich low-abundance proteins. Poor sample handling further reduces recovery through peptide adsorption to plastic surfaces and losses due to vacuum evaporation. We systematically mapped these losses across buffers, volumes, plastics and pH, then developed an Evotip-compatible handling protocol that minimises adsorption and removes the need for vacuum evaporation. Losses to plastic adsorption and vacuum evaporation were most apparent at low inputs (< 200 ng) and with larger volumes (> 20 µL) but were also dependent on acidification as well as the buffer and plastic used. The optimised workflow: direct acidification of peptides, frozen storage if needed, and direct loading onto Evotips, resulted in up to ~100-fold gains versus common drying practices. This optimised sample handling method enables high-throughput chemical proteomics by reducing manual handling steps and enables the characterisation of low abundance proteins previously lost during sample preparation.

2026-06-23 | PXD069322 | Pride